Clinical Trials Browser

Phase 2/3 × OTHER_GOV × Gynecologic × Clear all

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Phase 2/3 Unknown

Hydatidiform Mole, Gestational Trophoblastic Disease

NCT01091636 2020-02-17

Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer

Phase 2/3 Completed

Carcinoma, Ovarian Epithelial